Login to Your Account



Rapid Progress in ADCs

Next-Gen Drug Conjugates Attracting Funds, Partners

By Peter Winter
Editor

Monday, August 6, 2012

The field of research surrounding antibody-drug conjugates (ADCs) and other peptide and small-molecule drug conjugates has heated up in the last 12 months following the approval of Seattle Genetics Inc.'s Adcetris (brentuximab vedotin), an ADC directed to CD30, to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large-cell lymphoma. It was the first ADC to gain approval. (See BioWorld Today, Aug. 22, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription